Clinical trials: Extramembranous Glomerulopathy
Primary Membranous Nephropathy
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN
- Trial name
- PrisMN (NCT07096843)
- Testing
- budoprutug
- Where
- 38 sites in United States, Argentina and 5 more
- Volunteers
- 45 people
- Sponsor
- Climb Bio, Inc.
Lupus Nephritis, Membranous Nephropathy
Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial
Lupus nephritis (LN) is a frequent and severe complication of systemic lupus erythematosus, with important mortality and morbidity.
- Trial name
- OBLUMEN (NCT07721363)
- Testing
- Obinutuzumab
- Where
- France
- Volunteers
- 65 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and biological profiles of individuals of Middle Eastern, North African, and Levantine ancestry, including…
- Conditions
- Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- MERIT (NCT07892651)
- Where
- Jordan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Axiom Bioregistry
Membranous Nephropathy, Membranous Nephropathy - PLA2R Induced
Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy
The aim of this observational study is to provide analysis of T and B lymphocyte subgroups in peripheral blood samples of patients with primary membranous nephropathy (MN).
- Conditions
- Membranous Nephropathy, Membranous Nephropathy - PLA2R Induced, Membranous Nephropathy - THSD7A Induced
- Trial name
- NCT05894512
- Where
- Turkey (Türkiye)
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Istanbul University
Refractory Idiopathic Membranous Nephropathy
Clinical Study of Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN)
A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy…
- Trial name
- NCT07423572
- Testing
- CD19/BCMA-Targeted Universal Chimeric Antigen Receptor T Cells (UCAR-T) infusing
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The First Affiliated Hospital of Zhejiang Chinese Medical University
Primary Membranous Nephropathy
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
In this study, researchers will learn more about the use of felzartamab in participants with primary membranous nephropathy, also known as PMN. In people with PMN, autoantibodies build up in the glomeruli of the kidney.
- Trial name
- PROMINENT (NCT06962800)
- Testing
- Felzartamab, Tacrolimus, Standard of Care IST
- Where
- 114 sites in United States, Argentina and 9 more
- Volunteers
- 180 people
- Sponsor
- Biogen
Efficacy
Multitarget Therapy for Idiopathic Membranous Nephropathy
Membranous nephropathy (MN) is one of the commonest causes of nephrotic syndrome in adults, idiopathic membranous nephropathy (IMN) accounts for 70%-80% of all MN patients. There is no standard specific treatment for IMN.
- Trial name
- MTIMN (NCT04424862)
- Testing
- Prednisone, ciclosporin and mycophenolate mofetil, Ponticelli Regimen
- Where
- 2 sites in China
- Volunteers
- 82 people
- Sponsor
- Beijing Friendship Hospital
Membranous Nephropathy
MOR202 for Refractory MN
Membranous nephropathy (MN) - the leading cause of nephrotic syndrome (NS) in adults - is an immune-mediated disease that results from the deposition of immunoglobulins and complement components onto the sub-epithelial layer of…
- Trial name
- MONET (NCT04893096)
- Testing
- MOR202
- Where
- 2 sites in Italy
- Volunteers
- 10 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Idiopathic Membranous Nephropathy
Study on Single-nucleotide-polymorphism in Idiopathic Membranous Nephropathy
The purpose of this study is to analysis the different genotype in the idiopathic membranous nephropathy patients which with different therapeutic outcomes after treated by the Comprehensive Treatment Regimen or immunosuppressive…
- Trial name
- NCT01799460
- Testing
- The Comprehensive Treatment Regimen of Traditional Chinese Medicine, The immunosuppressive agents
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Shanghai University of Traditional Chinese Medicine
Membranous Nephropathy
Immunopathological Analysis in a French National Cohort of Membranous Nephropathy
National cohort of all cases of membranous nephropathy (MN) during a 1 year period in France, based on a pathological and/or serological diagnostic, collecting the data on: incidence of MN prevalence of anti-PLA2R1 and…
- Trial name
- IHMN (NCT04326218)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Primary Membranous Nephropathy, Minimal Change Disease
A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change Disease
This study will assess whether sibeprenlimab can help improve kidney disease in adults with primary membranous nephropathy (pMN) by reducing harmful antibodies linked to the disease.
- Conditions
- Primary Membranous Nephropathy, Minimal Change Disease, Focal Segmental Glomerulosclerosis
- Trial name
- NCT07861113
- Testing
- Sibeprenlimab
- Volunteers
- 20 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Membranous Nephropathy
Rituximab in Membranous Nephropathy
Membranous glomerulopathy (MN) is a common immune-mediated glomerular disease and the leading cause of nephrotic syndrome in Caucasian adults.
- Trial name
- NCT00425217
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Idiopathic Membranous Nephropathy
MEmbranous Nephropathy Trial Of Rituximab
The primary outcome of this study is to determine whether or not the B cell targeting with Rituximab is non-inferior or more effective than Cyclosporine in inducing long term remission of proteinuria.
- Trial name
- MENTOR (NCT01180036)
- Testing
- Rituximab, Cyclosporine
- Where
- 21 sites in United States, Canada
- Volunteers
- 130 people
- Sponsor
- Mayo Clinic
Idiopathic Membranous Nephropathy
Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy
The purpose of this study is to evaluate the clinical safety and efficacy of QingReMoShen Granule to treat idiopathic membranous nephropathy.
- Trial name
- NCT01845688
- Testing
- Losartan Tablets & QingReMoShen Granule
- Where
- China
- Volunteers
- 72 people
- Sponsor
- wanglin
Idiopathic Membranous Nephropathy
Aliskiren in Patients With Idiopathic Membranous Nephropathy
The goal of this proposal is to conduct a pilot study to access the antiproteinuric effect of aliskiren in patients with idiopathic membranous nephropathy.
- Trial name
- NCT01093781
- Testing
- Aliskiren
- Where
- United States
- Sponsor
- Mayo Clinic
Glomerulonephritis, Membranous, Neonatal Diseases and Abnormalities
Research Network for Neonatal Diseases Induced by Tissular Fetomaternal Alloimmunization
Problems of compatibility between a mother and her child are frequent. The most well-known case can be illustrated by the fetomaternal blood group incompatibility (rhesus factor) which can induce severe anemia of the fetus.
- Conditions
- Glomerulonephritis, Membranous, Neonatal Diseases and Abnormalities, Hemochromatosis
- Trial name
- NCT00199628
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Limoges
Membranous Nephropathy
Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy
Membranous Nephropathy (MN) is a renal autoimmune disease mediated by autoantibodies. Current management is based on the use of immunosuppressive therapies.
- Trial name
- ALPHAGEM (NCT05941845)
- Testing
- Peginterferon Alfa-2A 180 MCG/ML Injectable Solution
- Where
- France
- Volunteers
- 4 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Idiopathic Membranous Nephropathy
Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy
The Membranous Nephropathy is one of the most common cause of Nephrotic Syndrome of adults. In 2/3 of patients the cause of the disease is idiopathic.
- Trial name
- GEMRITUX (NCT01508468)
- Testing
- symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin), experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Proteinuria
Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
The primary objective of this study is to assess the impact of proteinuria on the pharmacokinetic (PK) of a single dose of ALXN1720 in participants with proteinuria.
- Trial name
- NCT05314231
- Testing
- ALXN1720
- Where
- 2 sites in South Korea
- Volunteers
- 13 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Glomerular Disease, Minimal Change Disease
KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
Glomerulonephritis (GN) generates an enormous individual and social economic burden. However, the therapeutic options are largely based on clinical and pathological parameters and the individual response to therapy or prognosis…
- Conditions
- Glomerular Disease, Minimal Change Disease, IgA Nephropathy, Membranous Nephropathy
- Trial name
- KORNERSTONE (NCT03929887)
- Testing
- Kidney Biopsy
- Where
- 6 sites in South Korea
- Volunteers
- 3,000 people
- Sponsor
- Seoul National University Hospital